Picture the family waiting room outside an intensive care unit. Your father was admitted overnight with sepsis, and a cousin in the group chat posts a link: in some countries, doctors give thymosin alpha-1 to sepsis patients to “rebalance the immune system.” Should you ask the ICU team about it, or even look for a research vial yourself?
The short answer comes from a large placebo-controlled phase 3 trial. In a study of more than 1,100 adults with sepsis, thymosin alpha-1 did not lower the chance of dying within 28 days compared with placebo.
Why sepsis care is a race against time
MedlinePlus describes sepsis as the body’s overactive and extreme response to an infection, and calls it a life-threatening medical emergency. Without quick treatment it can lead to tissue damage, organ failure, and death. That urgency sets the bar for any add-on treatment: it has to show that it changes outcomes for patients like the one in the bed.
The TESTS researchers describe thymosin alpha-1 as an immunomodulatory drug, meaning it is meant to change how the immune system responds. The hope behind testing it in sepsis was that this could improve survival. A hope is where a trial starts, not where it ends.
What the TESTS trial found
The TESTS trial, published in The BMJ in January 2025, was a multicentre, double-blinded, placebo-controlled phase 3 study at 22 hospitals in China, run from September 2016 to December 2020. It enrolled 1,106 adults aged 18 to 85 who met current sepsis criteria and randomly assigned them to thymosin alpha-1 injections or placebo during their first week of intensive care.
The main question was simple: how many people died from any cause within 28 days? In the analysed groups, 23.4% of the thymosin alpha-1 patients died, compared with 24.1% on placebo. The hazard ratio was 0.99, which means essentially no difference. No secondary outcome or safety outcome differed significantly between the groups either. The authors concluded that the trial found no clear evidence that thymosin alpha-1 decreases 28-day mortality in adults with sepsis.
Two details matter when you read headlines about this study. First, a prespecified subgroup analysis suggested the effect might differ by age and by diabetes status. Subgroup signals like these are reasons for future research, not proof that a particular patient would benefit, and in the under-60 group the estimate pointed in the unfavorable direction. Second, the paper’s disclosures list support from SciClone Pharmaceuticals, along with university and regional research funding. Company support does not make results wrong, but it is part of the full picture.
Where a research vial fits: it does not
An earlier Everyday Brief story covered thymosin alpha-1’s overseas licenses and its regulatory position in the United States. Research-catalog listings of thymosin alpha-1 are laboratory materials. They are not a hospital product, and nothing in the TESTS trial supports bringing outside materials into a critically ill person’s care.
What to do in the waiting room. If someone you love has sepsis, useful questions for the ICU team are about the source of infection, how the treatment plan is going, and whether any clinical trials are enrolling at that hospital. If the immune-booster link comes up, you now know a large placebo-controlled phase 3 trial did not find a survival benefit. Your energy is better spent on questions the care team can act on today.
Not medical advice.
Sources
- Wu J et al. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): phase 3 randomised trial. BMJ, 2025 (PubMed)
- TESTS trial full text (PubMed Central)
- ClinicalTrials.gov record NCT02867267 (TESTS)
- MedlinePlus: Sepsis
Related reading
- Thymosin alpha-1 ads, the U.S. approval gap, and a missed endpoint
- VIP research listings and hospital aviptadil trial results
- A relative says Semax is a stroke drug: what the studies show
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-13 PT. Not medical advice.